| GERON CORP. (DEL.) DL-001 |
| USA |
| Gesundheit |
| US3741631036 / 902213 |
| GON (Frankfurt) / GERN (NASDAQ) |
| FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN |
| - |
| https://www.geron.com/ |
|
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the tre..
>Volltext.. |
| 848.55 Mio. EUR |
| 803.66 Mio. EUR |
| 176.58 Mio. EUR |
| -31.35 Mio. EUR |
| -60.34 Mio. EUR |
| -0.09 EUR |
| 217.34 Mio. EUR |
| 55.71 Mio. EUR |
| -98.73 Mio. EUR |
| 4.3 |
| 28.3% |
| 18.08% |
| - |
| - |
| - |
| - |
| GERON |
| 02.09.26 |
|
||||
|